[{"indications": "Indications\u00a0urinary frequency, urgency and incontinence, neurogenic bladder instability,\r\nand nocturnal enuresis associated with overactive bladder", "name": "OXYBUTYNIN HYDROCHLORIDE Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "7 Obstetrics, gynaecology, and urinary-tract disorders", "7.4 Drugs for genito-urinary disorders", "7.4.2 Drugs for urinary frequency, enuresis, and incontinence", "Urinary incontinence", "OXYBUTYNIN HYDROCHLORIDE", "Modified release"], "cautions": "Cautions\u00a0\n(From Urinary incontinence: British National Formulary)\nCautions\u00a0Antimuscarinic drugs should be used with caution in the elderly (especially if frail), in those with autonomic neuropathy, and in those susceptible to angle-closure glaucoma. They should also be used with caution in hiatus hernia with reflux oesophagitis. Antimuscarinics can worsen hyperthyroidism, coronary artery disease, congestive heart failure, hypertension, prostatic hyperplasia, arrhythmias, and tachycardia. For interactions, see Appendix 1 (antimuscarinics).; acute porphyria  (%s\n(From 9.8.2 Acute porphyrias: British National Formulary)\n9.8.2 Acute porphyrias)", "side-effects": "Side-effects\u00a0\n(From Urinary incontinence: British National Formulary)\nSide-effects\u00a0Side-effects of antimuscarinic drugs include dry mouth, gastro-intestinal disturbances including constipation, flatulence, taste disturbances, blurred vision, dry eyes, drowsiness, dizziness, fatigue, difficulty in micturition (less commonly urinary retention), palpitation, and skin reactions (including dry skin, rash, and photosensitivity); also headache, diarrhoea, angioedema, arrhythmias, and tachycardia. Central nervous system stimulation, such as restlessness, disorientation, hallucination, and convulsion may occur; children are at higher risk of these effects. Antimuscarinic drugs can reduce sweating, leading to heat sensations and fainting in hot environments or in patients with fever, and very rarely may precipitate angle-closure glaucoma.; also less commonly anorexia, facial flushing; rarely night terrors; application site reactions with patches; also reported cognitive impairment", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/88024.htm", "doses": ["adult and child over 12 years, initially 5\u00a0mg 2\u20133 times daily,\r\nincreased if necessary to max. 5\u00a0mg 4 times daily; elderly initially 2.5\u20133\u00a0mg twice daily, increased\r\nto 5\u00a0mg twice daily according to response and tolerance; child 5\u201312 years, neurogenic bladder instability,\r\n2.5\u20133\u00a0mg twice daily, increased to 5\u00a0mg 2\u20133 times daily; child under 5 years see BNF for Children; child 5\u201318 years, nocturnal enuresis associated with\r\noveractive bladder, 2.5\u20133\u00a0mg twice daily increased to 5\u00a0mg 2\u20133 times\r\ndaily (last dose before bedtime)", "Name[Lyrinel\u00ae XL (Janssen) ] Tablets, m/r, oxybutynin\r\nhydrochloride 5\u00a0mg (yellow), net price 30-tab pack = \u00a313.77;\r\n10\u00a0mg (pink), 30-tab pack = \u00a327.54. \r\n    Label:\r\n    3, 25Dose\u00a0initially 5\u00a0mg once daily, adjusted according to response\r\nin steps of 5\u00a0mg at weekly intervals; max. 20\u00a0mg once daily; child over 6 years, neurogenic bladder instability,\r\ninitially 5\u00a0mg once daily, adjusted according to response in steps\r\nof 5\u00a0mg at weekly intervals; max. 15\u00a0mg once dailyNote\u00a0Patients taking immediate-release oxybutynin\r\nmay be transferred to the nearest equivalent daily dose of Lyrinel\u00ae XL"], "pregnancy": "Pregnancy\u00a0manufacturers advise avoid unless essential\u2014toxicity\r\nin animal studies"}, {"indications": "Indications\u00a0urinary frequency, urgency and incontinence, neurogenic bladder instability,\r\nand nocturnal enuresis associated with overactive bladder", "name": "OXYBUTYNIN HYDROCHLORIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "7 Obstetrics, gynaecology, and urinary-tract disorders", "7.4 Drugs for genito-urinary disorders", "7.4.2 Drugs for urinary frequency, enuresis, and incontinence", "Urinary incontinence", "OXYBUTYNIN HYDROCHLORIDE"], "cautions": "Cautions\u00a0\n(From Urinary incontinence: British National Formulary)\nCautions\u00a0Antimuscarinic drugs should be used with caution in the elderly (especially if frail), in those with autonomic neuropathy, and in those susceptible to angle-closure glaucoma. They should also be used with caution in hiatus hernia with reflux oesophagitis. Antimuscarinics can worsen hyperthyroidism, coronary artery disease, congestive heart failure, hypertension, prostatic hyperplasia, arrhythmias, and tachycardia. For interactions, see Appendix 1 (antimuscarinics).; acute porphyria  (%s\n(From 9.8.2 Acute porphyrias: British National Formulary)\n9.8.2 Acute porphyrias)", "side-effects": "Side-effects\u00a0\n(From Urinary incontinence: British National Formulary)\nSide-effects\u00a0Side-effects of antimuscarinic drugs include dry mouth, gastro-intestinal disturbances including constipation, flatulence, taste disturbances, blurred vision, dry eyes, drowsiness, dizziness, fatigue, difficulty in micturition (less commonly urinary retention), palpitation, and skin reactions (including dry skin, rash, and photosensitivity); also headache, diarrhoea, angioedema, arrhythmias, and tachycardia. Central nervous system stimulation, such as restlessness, disorientation, hallucination, and convulsion may occur; children are at higher risk of these effects. Antimuscarinic drugs can reduce sweating, leading to heat sensations and fainting in hot environments or in patients with fever, and very rarely may precipitate angle-closure glaucoma.; also less commonly anorexia, facial flushing; rarely night terrors; application site reactions with patches; also reported cognitive impairment", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/61077.htm", "doses": ["adult and child over 12 years, initially 5\u00a0mg 2\u20133 times daily,\r\nincreased if necessary to max. 5\u00a0mg 4 times daily; elderly initially 2.5\u20133\u00a0mg twice daily, increased\r\nto 5\u00a0mg twice daily according to response and tolerance; child 5\u201312 years, neurogenic bladder instability,\r\n2.5\u20133\u00a0mg twice daily, increased to 5\u00a0mg 2\u20133 times daily; child under 5 years see BNF for Children; child 5\u201318 years, nocturnal enuresis associated with\r\noveractive bladder, 2.5\u20133\u00a0mg twice daily increased to 5\u00a0mg 2\u20133 times\r\ndaily (last dose before bedtime)"], "pregnancy": "Pregnancy\u00a0manufacturers advise avoid unless essential\u2014toxicity\r\nin animal studies"}, {"indications": "Indications\u00a0urinary frequency, urgency and incontinence, neurogenic bladder instability,\r\nand nocturnal enuresis associated with overactive bladder", "name": "OXYBUTYNIN HYDROCHLORIDE Transdermal preparations", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "7 Obstetrics, gynaecology, and urinary-tract disorders", "7.4 Drugs for genito-urinary disorders", "7.4.2 Drugs for urinary frequency, enuresis, and incontinence", "Urinary incontinence", "OXYBUTYNIN HYDROCHLORIDE", "Transdermal preparations"], "cautions": "Cautions\u00a0\n(From Urinary incontinence: British National Formulary)\nCautions\u00a0Antimuscarinic drugs should be used with caution in the elderly (especially if frail), in those with autonomic neuropathy, and in those susceptible to angle-closure glaucoma. They should also be used with caution in hiatus hernia with reflux oesophagitis. Antimuscarinics can worsen hyperthyroidism, coronary artery disease, congestive heart failure, hypertension, prostatic hyperplasia, arrhythmias, and tachycardia. For interactions, see Appendix 1 (antimuscarinics).; acute porphyria  (%s\n(From 9.8.2 Acute porphyrias: British National Formulary)\n9.8.2 Acute porphyrias)", "side-effects": "Side-effects\u00a0\n(From Urinary incontinence: British National Formulary)\nSide-effects\u00a0Side-effects of antimuscarinic drugs include dry mouth, gastro-intestinal disturbances including constipation, flatulence, taste disturbances, blurred vision, dry eyes, drowsiness, dizziness, fatigue, difficulty in micturition (less commonly urinary retention), palpitation, and skin reactions (including dry skin, rash, and photosensitivity); also headache, diarrhoea, angioedema, arrhythmias, and tachycardia. Central nervous system stimulation, such as restlessness, disorientation, hallucination, and convulsion may occur; children are at higher risk of these effects. Antimuscarinic drugs can reduce sweating, leading to heat sensations and fainting in hot environments or in patients with fever, and very rarely may precipitate angle-closure glaucoma.; also less commonly anorexia, facial flushing; rarely night terrors; application site reactions with patches; also reported cognitive impairment", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129279.htm", "doses": ["adult and child over 12 years, initially 5\u00a0mg 2\u20133 times daily,\r\nincreased if necessary to max. 5\u00a0mg 4 times daily; elderly initially 2.5\u20133\u00a0mg twice daily, increased\r\nto 5\u00a0mg twice daily according to response and tolerance; child 5\u201312 years, neurogenic bladder instability,\r\n2.5\u20133\u00a0mg twice daily, increased to 5\u00a0mg 2\u20133 times daily; child under 5 years see BNF for Children; child 5\u201318 years, nocturnal enuresis associated with\r\noveractive bladder, 2.5\u20133\u00a0mg twice daily increased to 5\u00a0mg 2\u20133 times\r\ndaily (last dose before bedtime)", "Name[Kentera\u00ae (Orion) ] Patches, self-adhesive, oxybutynin\r\n36\u00a0mg (releasing oxybutynin approx. 3.9\u00a0mg/24 hours), net price 8-patch\r\npack = \u00a327.20. \r\n    Label:\r\n    3, counselling, administrationDose\u00a0adult over 18 years, urinary\r\nfrequency, urgency and incontinence, apply 1 patch twice weekly to\r\nclean, dry, unbroken skin on abdomen, hip or buttock, remove after\r\nevery 3\u20134 days and site replacement patch on a different area (avoid\r\nusing same area for 7 days)Note\u00a0The Scottish Medicines Consortium has advised (July 2005) that Kentera\u00ae should be\r\nrestricted for use in patients who benefit from oral oxybutynin but\r\ncannot tolerate its side-effects"], "pregnancy": "Pregnancy\u00a0manufacturers advise avoid unless essential\u2014toxicity\r\nin animal studies"}]